×
XOMA Royalty Common Stock Net 2010-2024 | XOMA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
XOMA Royalty common stock net from 2010 to 2024. Common stock net can be defined as the value of common equity ownership.
View More
XOMA Royalty Common Stock Net 2010-2024 | XOMA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
XOMA Royalty common stock net from 2010 to 2024. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$141B
Bristol Myers Squibb (BMY)
$113.2B
Gilead Sciences (GILD)
$112B
Vertex Pharmaceuticals (VRTX)
$105.5B
CSL (CSLLY)
$84.4B
Regeneron Pharmaceuticals (REGN)
$76.6B
GSK (GSK)
$68.6B
Argenex SE (ARGX)
$39.6B
Alnylam Pharmaceuticals (ALNY)
$30.7B
BioNTech SE (BNTX)
$29.5B
Biogen (BIIB)
$21.7B
Illumina (ILMN)
$21.7B
BeiGene (ONC)
$17.3B
Moderna (MRNA)
$16.3B
Genmab (GNMSF)
$14.7B
Genmab (GMAB)
$14.7B
Incyte (INCY)
$13.6B
BioMarin Pharmaceutical (BMRN)
$12.8B
Sarepta Therapeutics (SRPT)
$11.9B
Insmed (INSM)
$11.7B
Bio-Techne Corp (TECH)
$11.6B
Exact Sciences (EXAS)
$10.5B
Exelixis (EXEL)
$10.3B
QIAGEN (QGEN)
$10.2B
Vaxcyte (PCVX)
$10.1B
Swedish Orphan Biovitrum (BIOVF)
$10.1B
Intra-Cellular Therapies (ITCI)
$10.1B
Bio-Rad Laboratories (BIO.B)
$9.5B
Repligen (RGEN)
$8.7B
Ascendis Pharma (ASND)
$7.8B